Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

A Phase 1 Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults

This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.

Key Inclusion Criteria:

• Adult 18-40 years of age
• In good health based on review of the medical record, history, and physical examination, without evidence of chronic disease
• RSV 'sero-low' from a pre-vaccination serum sample
• Signed informed consent form

Exclusion Criteria:

• Occupational or household exposure to children < 5 years of age, or to immunocompromised individuals
• Prior receipt of an investigational RSV vaccine
• Women who are pregnant, lactating, or unwilling to take effective measures to prevent pregnancy for at least 3 months after vaccination
• Any other reason the Investigator considers exclusionary